Posts

WuXi AppTec Added to Pentagon's List of Companies Linked to Chinese Military: What You Need to Know | Mid‑June 2026 Update

on
The Pentagon has added WuXi AppTec to its updated Section 1260H list of "Chinese military companies," which it says are linked to China's military or defense industrial base. WuXi AppTec is described as a major Chinese pharmaceutical contractor and contract research, development, and manufacturing organization (CRDMO) based in Shanghai. The Pentagon's notice links WuXi AppTec to a Chinese state‑owned assets supervisory commission and to the People's Liberation Army (PLA) and China's defense industrial sector, though WuXi AppTec denies any military control or affiliation. The designation means that U.S. defense agencies are barred from directly contracting with WuXi AppTec and, starting in 2027, from procuring its products or services through third parties. WuXi AppTec has rejected the Pentagon's decision, calling it a "clearly a mistake" and saying it intends to challenge the designation and pursue legal remedies to be removed from the li...

Parabilis’ record $670M IPO to fund cancer drug and platform expansion

on

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

on

GT Medical Technologies Completes $100 Million Series E to Advance GammaTile in Operable Brain Tumors

on

GSK acquires lung‑cancer specialist Nuvalent for $10.6 billion

on

WuXi AppTec lands on Pentagon blacklist, facing Biosecure ban

on

Who pays the best (and worst) in biopharma? A look at typical employee salaries

on

Oral GLP‑1 Tracker: Novo’s oral Wegovy hits 3M prescription milestone as Lilly’s Foundayo chugs along in early launch

on

City Therapeutics raises $99.5M to advance three RNAi programs and its next‑generation platform

on

GSK to Acquire Nuvalent and Its Two Cancer Drugs Under FDA Review for $10.6 Billion

on

Lilly Offers Up to $1B for Alzheimer's Drug

on

Trodelvy misses lung cancer endpoint, but Gilead and Merck score HIV win with weekly combo

on

ADA: AZ’s oral GLP‑1 shows competitive efficacy in phase 2, setting stage for pivotal program

on